NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Spotlights Positive Results From NeutroPhase(R) Study of 26 Patients With Chronic Non-Healing Wounds

EMERYVILLE, Calif., April 19, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, presented a poster on the efficacy of NeutroPhase® solution (NVC-101) with the hydrophobic mesh Sorbact® in healing chronic non-healing wounds at the 2011 Symposium on Advanced Wound Care (SAWC) in Dallas on April 15-16.